CertolizumabPegol injection ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05651373 (ClinicalTrials.gov) | July 30, 2021 | 15/11/2022 | The Clinical Features and Pregnancy Outcomes of RA Patients | The Clinical Features and Pregnancy Outcomes of Patients With Rheumatoid Arthritis :a Prospective Cohort Study | Rheumatoid Arthritis;Pregnancy Related | Drug: Prednisone;Drug: Hydroxychloroquine;Drug: CertolizumabPegol injection | Qilu Hospital of Shandong University | NULL | Recruiting | 20 Years | 45 Years | Female | 100 | China |